Overexpression of epidermal growth factor receptor as a prognostic factor in colorectal cancer on the basis of the Allred scoring system

OncoTargets and Therapy

Volumn 6, Issue , 2013, Pages 967-976

  Rokita, Marta ^a   Stec, Rafał ^a   Bodnar, Lubomir ^a   Charkiewicz, Radosław ^b   Korniluk, Jan ^a   Smoter, Marta ^a   Cichowicz, Marzena ^a   Chyczewski, Lech ^b   Nikliński, Jacek ^b   Kozłowski, Wojciech ^a   Szczylik, Cezary ^a  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

^b MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Cancer; Expression; Prognosis; Receptor

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; ALLRED SCORING SYSTEM; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL FEATURE; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SCORING SYSTEM; TUMOR LOCALIZATION;

EID: 84880801478     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S42446     Document Type: Article

References (42)

1. Hawk ET, Linburg PJ, Viner JL. Epidemiology and prevention of colorectal cancer. Surg Clin North Am. 2002;82(5):905-941.
2. Spano JP, Lagorce C, Atlan D, et al. Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol. 2005;16(1): 102-108.
3. Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer. 2001;92(5):1331-1346.
4. Rego RL, Foster NR, Smyrk TC, et al. Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status. Br J Cancer. 2010;102(1):165-172.
5. Krasinskas AM. EGFR Signaling in colorectal carcinoma. Patholog Res Int. 2011;2011:932932.
6. Citri A, Yarden Y. EGF-ERBB signaling: towards the systems level. Nat Rev Mol Cell Biol. 2006;7(7):505-516.
7. Komuta K, Koji T, Izumi S, et al. Expression of epidermal growth factor receptor messenger RNA in human colorectal carcinomas assessed by non-radioactive in-situ hybridization. Eur J Surg Oncol. 1995;21(3):269-275.
8. Shia J, Klimstra DS, Li AR, et al. Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study. Mod Pathol. 2005;18(10):1350-1356.
9. Pericay C, Santos-Vivas C, Pous-Saltor E, et al. Epidermal growth factor receptor (EGFR) as a prognostic factor over 10 years in non-metastatic colon carcinoma (NMCC). J Clin Oncol (ASCO Meeting Abstracts). 2007;25(Suppl 18):S21062. Abstract.
10. Maurizi M, Almadori G, Ferrandina G, et al. Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br J Cancer. 1996;74(8):1253-1257.
11. Fischer-Colbrie J, Witt A, Heinzl H, et al. EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. Anticancer Res. 1997;17(1B):613-619.
12. Kersemaekers AM, Fleuren GJ, Kenter GG, et al. Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clin Cancer Res. 1999;5(3):577-586.
13. Mellon K, Wright C, Kelly P, Horne CH, Neal DE. Long-term outcome related to epidermal growth factor receptor status in bladder cancer. J Urol. 1995;153(3 Pt 2):919-925.
14. Inada S, Koto T, Futami K, Arima S, Iwashita A. Evaluation of malignancy and the prognosis of esophageal cancer based on an immunohistochemical study (p53, E-cadherin, epidermal growth factor receptor). Surg Today. 1999;29(6):493-503.
15. Messa C, Russo F, Caruso MG, Di Leo A. EGF, TGF-alpha, and EGFR-R in human colorectal adenocarcinoma. Acta Oncol. 1998;37(3): 285-289.
16. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC Cancer Staging Handbook. 7th ed. New York: Springer-Verlag;2010.
17. Lenz HJ, Van Cutsem E, Khambata-Ford S, et al. Multicenter phase II and transational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluoropirymidines. J Clin Oncol. 2006;24(30):4914-4921.
18. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tremors that do not express the epidermal growth factor receptor by immunostaining. J Clin Oncol. 2005;23(9):1803-1810.
19. Hebbar M, Wacrenier A, Deesauw C, et al. Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer. Anticancer Drugs. 2006;17(7):855-857.
20. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11(2):155-168.
21. Oken MM, Creech RH, Tormey DC, et al. Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649-655.
22. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127-137.
23. Radinsky R, Risin S, Fan D, et al. Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin Cancer Res. 1995;1(1):19-31.
24. McKay JA, Murray LJ, Curran S, et al. Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur J Cancer. 2002;38(17):2258-2264.
25. Wan CW, McKnight MK, Brattain DE, Brattain MG, Yeoman LC. Different epidermal growth factor growth responses and receptor levels in human colon carcinoma cell lines. Cancer Lett. 1988;43(1-2): 139-143.
26. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351(4):337-345.
27. Garcia I, Vizoso F, Martin A, et al. Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol. 2003;10(3):234-241.
28. Kopp R, Rothbauer E, Ruge M, et al. Clinical implications of the EGF receptor/ligand system for tumor progression and survival in gastrointestinal carcinomas: evidence for new therapeutic options. Recent Results Cancer Res. 2003;162:115-132.
29. Gamboa-Dominguez A, Dominguez-Fonseca C, Quintanilla-Martinez L, et al. Epidermal growth factor expression correlates with poor survival in gastric adenocarcinoma from Mexican patients: a multivariate analysis using a standardized immunohistochemical detection system. Mod Pathol. 2004;17(5):579-587.
30. Ito R, Nakayama H, Yoshida K, Matsumura S, Oda N, Yasui W. Expression of Cbl linking with the epidermal growth factor receptor system is associated with tumor progression and poor prognosis of human gastric carcinoma. Virchows Asch. 2004;444(4):324-331.
31. Galizia G, Lieto E, Orditura M, et al. Epidermal growth factor receptor (EGFR) expression is associated with worse prognosis in gastric cancer patients undergoing curative surgery. World J Surg. 2007;31(7):1458-1468.
32. Golshayan AR, George S, Heng DY, et al. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol. 2009;27(2):235-241.
33. Mayer A, Takimoto M, Fritz E, Schellander G, Kofler K, Ludwig H. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer. 1993;71(8):2454-2460.
34. Koenders PG, Peters WH, Wobbes T, Beex LV, Nagengast FM, Benraad TJ. Epidermal growth factor receptor levels are lower in carcinomatous than in normal colorectal tissue. Br J Cancer. 1992;65(2):189-192.
35. Steele RJ, Kelly P, Ellul B, Eremin O. Immunohistochemical detection of epidermal growth factor receptors on human colonic carcinomas. Br J Cancer. 1990;61(2):325-326.
36. Koretz K, Schlag P, Möller P. Expression of epidermal growth factor receptor in normal colorectal mucosa, adenoma, and carcinoma. Virchows Arch A Pathol Anat Histopathol. 1990;416(4):343-349.
37. Moorghen M, Ince P, Finney KJ, Watson AJ, Harris AL. Epidermal growth factor receptors in colorectal carcinoma. Anticancer Res. 1990;10(3):605-611.
38. Karameris A, Kanavaros P, Aninos D, et al. Expression of epidermal growth factor (EGF) and epidermal growth factor receptor (EGFR) in gastric and colorectal carcinomas. An immunohistological study of 63 cases. Pathol Res Pract. 1993;189(2):133-137.
39. Steele RJ, Kelly P, Ellul B, Eremin O. Epidermal growth factor receptor expression in colorectal cancer. Br J Surg. 1990;77(12):1352-1354.
40. Atkins D, Rieffen KA, Tegtmeier CL, Winther H, Bonato MS, Störkel S. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem. 2004;52(7):893-901.
41. Beer MW, Ung C, Bacus SS, et al. Heterogeneity of epidermal growth factor receptor (EGFR) expression and variation in immunohistochemistry (ICH) testing may affect access to EGFR targeted therapy in patients with advanced colorectal cancer (CRC). J Clin Oncol (ASCO Meeting Abstracts). 2006;24(Suppl 18):S10104. Abstract.
42. Scartozzi M, Bearzi I, Berardi R, Mandolesi A, Fabris G, Cascinu S. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol. 2004;22(23):4720-4728.